Abstract
N-Acetylcysteine (NAC) is both a prescription medication and over-the-counter supplement that has been widely used in medicine. Its potential is being realized in other areas of medicine including gastrointestinal (GI) disease. NAC was first studied in GI disease in the 1960s in the context of cystic fibrosis for ileus, abdominal pain, and fat malabsorption. It was then researched in the context of acute and chronic liver failure, pancreatitis, liver surgery, and improving visualization for endoscopy. Some areas of GI disorders have adequate number of good quality trials to make recommendations. Overall, there are mixed but promising findings in the treatment of non-acetaminophen-induced liver failure, particularly acute liver failure. The effectiveness of NAC may depend on the etiology of chronic liver failure, and currently there are active clinical trials on the use of NAC for the treatment of alcohol-induced hepatitis and in the prevention of iatrogenic-induced liver injury, particularly as a result of antituberculous medication, liver failure and in the development of fatty liver. Two other areas that are very promising is in improving outcomes in liver transplantation, particularly when treating the donor liver, and in improving visualization in endoscopy. NAC does not appear to have a role in the treatment or management of pancreatitis. The use of NAC in treating abdominal discomfort and ileus in patients with cystic fibrosis is promising, but it is based on uncontrolled observational studies. Overall, there appear to be many potential uses for NAC in GI disorders, but for other disorders, further studies are needed to define the dosing and/or better define the subpopulation of patients which would most benefit from the treatment.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Asl SM, Sivandzadeh GR (2011) Efficacy of premedication with activated Dimethicone or N-acetylcysteine in improving visibility during upper endoscopy. World J Gastroenterol 17(37):4213–4217. https://doi.org/10.3748/wjg.v17.i37.4213
Baniasadi S, Eftekhari P, Tabarsi P, Fahimi F, Raoufy MR, Masjedi MR, Velayati AA (2010) Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity. Eur J Gastroenterol Hepatol 22(10):1235–1238. https://doi.org/10.1097/MEG.0b013e32833aa11b
Bernhard MC, Junker E, Hettinger A, Lauterburg BH (1998) Time course of total cysteine, glutathione and homocysteine in plasma of patients with chronic hepatitis C treated with interferon-alpha with and without supplementation with N-acetylcysteine. J Hepatol 28(5):751–755
Bromley PN, Cottam SJ, Hilmi I, Tan KC, Heaton N, Ginsburg R, Potter DR (1995) Effects of intraoperative N-acetylcysteine in orthotopic liver transplantation. Br J Anaesth 75(3):352–354
Bucuvalas JC, Ryckman FC, Krug S, Alonso MH, Balistreri WF, Kotagal U (2001) Effect of treatment with prostaglandin E1 and N-acetylcysteine on pediatric liver transplant recipients: a single-center study. Pediatr Transplant 5(4):274–278
Chang CC, Chen SH, Lin CP, Hsieh CR, Lou HY, Suk FM, Pan S, Wu MS, Chen JN, Chen YF (2007) Premedication with pronase or N-acetylcysteine improves visibility during gastroendoscopy: an endoscopist-blinded, prospective, randomized study. World J Gastroenterol 13(3):444–447
Chang WK, Yeh MK, Hsu HC, Chen HW, Hu MK (2014) Efficacy of simethicone and N-acetylcysteine as premedication in improving visibility during upper endoscopy. J Gastroenterol Hepatol 29(4):769–774. https://doi.org/10.1111/jgh.12487
Chen MJ, Wang HY, Chang CW, Hu KC, Hung CY, Chen CJ, Shih SC (2013) The add-on N-acetylcysteine is more effective than dimethicone alone to eliminate mucus during narrow-band imaging endoscopy: a double-blind, randomized controlled trial. Scand J Gastroenterol 48(2):241–245. https://doi.org/10.3109/00365521.2012.749509
D’Amico F, Vitale A, Piovan D, Bertacco A, Ramirez Morales R, Chiara Frigo A, Bassi D, Bonsignore P, Gringeri E, Valmasoni M, Garbo G, Lodo E, D'Amico FE, Scopelliti M, Carraro A, Gambato M, Brolese A, Zanus G, Neri D, Cillo U (2013) Use of N-acetylcysteine during liver procurement: a prospective randomized controlled study. Liver Transpl 19(2):135–144. https://doi.org/10.1002/lt.23527
Gracey M, Burke V, Anderson CM (1969) Treatment of abdominal pain in cystic fibrosis by oral administration of n-acetyl cysteine. Arch Dis Child 44(235):404–405
Grendar J, Ouellet JF, McKay A, Sutherland FR, Bathe OF, Ball CG, Dixon E (2016) Effect of N-acetylcysteine on liver recovery after resection: a randomized clinical trial. J Surg Oncol 114(4):446–450. https://doi.org/10.1002/jso.24312
Hanly JG, Fitzgerald MX (1983) Meconium ileus equivalent in older patients with cystic fibrosis. Br Med J (Clin Res Ed) 286(6375):1411–1413
Hilmi IA, Peng Z, Planinsic RM, Damian D, Dai F, Tyurina YY, Kagan VE, Kellum JA (2010) N-acetylcysteine does not prevent hepatorenal ischaemia-reperfusion injury in patients undergoing orthotopic liver transplantation. Nephrol Dial Transplant 25(7):2328–2333. https://doi.org/10.1093/ndt/gfq077
Katsinelos P, Kountouras J, Paroutoglou G, Beltsis A, Mimidis K, Zavos C (2005) Intravenous N-acetylcysteine does not prevent post-ERCP pancreatitis. Gastrointest Endosc 62(1):105–111
Lee WM, Hynan LS, Rossaro L, Fontana RJ, Stravitz RT, Larson AM, Davern TJ 2nd, Murray NG, McCashland T, Reisch JS, Robuck PR (2009) Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology 137(3):856–864, 864.e851. https://doi.org/10.1053/j.gastro.2009.06.006
Lillibridge CB, Docter JM, Eidelman S (1967) Oral administration of n-acetyl cysteine in the prophylaxis of “meconium ileus equivalent”. J Pediatr 71(6):887–889
Milewski J, Rydzewska G, Degowska M, Kierzkiewicz M, Rydzewski A (2006) N-acetylcysteine does not prevent post-endoscopic retrograde cholangiopancreatography hyperamylasemia and acute pancreatitis. World J Gastroenterol 12(23):3751–3755
Mitchell EA, Elliott RB (1981) Failure of oral N-acetylcysteine to improve the malabsorption of cystic fibrosis. Aust Paediatr J 17(3):207–208
Moreno C, Langlet P, Hittelet A, Lasser L, Degre D, Evrard S, Colle I, Lemmers A, Deviere J, Le Moine O (2010) Enteral nutrition with or without N-acetylcysteine in the treatment of severe acute alcoholic hepatitis: a randomized multicenter controlled trial. J Hepatol 53(6):1117–1122. https://doi.org/10.1016/j.jhep.2010.05.030
Neale JR, James S, Callaghan J, Patel P (2013) Premedication with N-acetylcysteine and simethicone improves mucosal visualization during gastroscopy: a randomized, controlled, endoscopist-blinded study. Eur J Gastroenterol Hepatol 25(7):778–783. https://doi.org/10.1097/MEG.0b013e32836076b2
Nguyen-Khac E, Thevenot T, Piquet MA, Benferhat S, Goria O, Chatelain D, Tramier B, Dewaele F, Ghrib S, Rudler M, Carbonell N, Tossou H, Bental A, Bernard-Chabert B, Dupas JL (2011) Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med 365(19):1781–1789. https://doi.org/10.1056/NEJMoa1101214
Pamuk GE, Sonsuz A (2003) N-acetylcysteine in the treatment of non-alcoholic steatohepatitis. J Gastroenterol Hepatol 18(10):1220–1221
Perman J, Breslow L, Ingal D (1975) Nonoperative treatment of meconium ileus equivalent. Am J Dis Child 129(10):1210–1211
Regueira FM, Cienfuegos JA, Pardo F, Hernandez JL, Diez-Caballero A, Sierra A, Nwose E, Espi A, Baixauli J, Rotellar F (1997) Improvement in early function of the hepatic graft after treatment of the donor with N-acetylcysteine: clinical study. Transplant Proc 29(8):3350–3352
Shi XF, Guo SH, Wu G, Mao Q, Yu YS, Wang JK, Zhang L, Wang ZY, Zhang XQ, Zhang QH, Zhao YR, Zeng WQ (2005) [A multi-center clinical study of N-acetylcysteine on chronic hepatitis B]. Zhonghua Gan Zang Bing Za Zhi 13(1):20–23
Singh S, Hynan LS, Lee WM (2013) Improvements in hepatic serological biomarkers are associated with clinical benefit of intravenous N-acetylcysteine in early stage non-acetaminophen acute liver failure. Dig Dis Sci 58(5):1397–1402. https://doi.org/10.1007/s10620-012-2512-x
Siriwardena AK, Mason JM, Balachandra S, Bagul A, Galloway S, Formela L, Hardman JG, Jamdar S (2007) Randomised, double blind, placebo controlled trial of intravenous antioxidant (n-acetylcysteine, selenium, vitamin C) therapy in severe acute pancreatitis. Gut 56(10):1439–1444. https://doi.org/10.1136/gut.2006.115873
Snyder WH Jr, Gwinn JL, Landing BH, Asay LD (1964) Fecal retention in children with cystic fibrosis. Report of three cases. Pediatrics 34:72–77
Squires RH, Dhawan A, Alonso E, Narkewicz MR, Shneider BL, Rodriguez-Baez N, Olio DD, Karpen S, Bucuvalas J, Lobritto S, Rand E, Rosenthal P, Horslen S, Ng V, Subbarao G, Kerkar N, Rudnick D, Lopez MJ, Schwarz K, Romero R, Elisofon S, Doo E, Robuck PR, Lawlor S, Belle SH (2013) Intravenous N-acetylcysteine in pediatric patients with nonacetaminophen acute liver failure: a placebo-controlled clinical trial. Hepatology 57(4):1542–1549. https://doi.org/10.1002/hep.26001
Steib A, Freys G, Collin F, Launoy A, Mark G, Boudjema K (1998) Does N-acetylcysteine improve hemodynamics and graft function in liver transplantation? Liver Transpl Surg 4(2):152–157
Stravitz RT, Sanyal AJ, Reisch J, Bajaj JS, Mirshahi F, Cheng J, Lee WM (2013) Effects of N-acetylcysteine on cytokines in non-acetaminophen acute liver failure: potential mechanism of improvement in transplant-free survival. Liver Int 33(9):1324–1331. https://doi.org/10.1111/liv.12214
Thies JC, Teklote J, Clauer U, Tox U, Klar E, Hofmann WJ, Herfarth C, Otto G (1998) The efficacy of N-acetylcysteine as a hepatoprotective agent in liver transplantation. Transpl Int 11(Suppl 1):S390–S392
Virlos IT, Mason J, Schofield D, McCloy RF, Eddleston JM, Siriwardena AK (2003) Intravenous n-acetylcysteine, ascorbic acid and selenium-based anti-oxidant therapy in severe acute pancreatitis. Scand J Gastroenterol 38(12):1262–1267
Wang N, Shi XF, Guo SH, Zhang DZ, Ren H (2008) [A clinical study of N-acetylcysteine treatment in chronic hepatitis B patients]. Zhonghua Gan Zang Bing Za Zhi 16(7):487–489
Weigand MA, Plachky J, Thies JC, Spies-Martin D, Otto G, Martin E, Bardenheuer HJ (2001) N-acetylcysteine attenuates the increase in alpha-glutathione S-transferase and circulating ICAM-1 and VCAM-1 after reperfusion in humans undergoing liver transplantation. Transplantation 72(4):694–698
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Frye, R.E. (2019). The Clinical Use of N-Acetylcysteine in Gastrointestinal Disorders. In: Frye, R., Berk, M. (eds) The Therapeutic Use of N-Acetylcysteine (NAC) in Medicine. Adis, Singapore. https://doi.org/10.1007/978-981-10-5311-5_17
Download citation
DOI: https://doi.org/10.1007/978-981-10-5311-5_17
Published:
Publisher Name: Adis, Singapore
Print ISBN: 978-981-10-5310-8
Online ISBN: 978-981-10-5311-5
eBook Packages: MedicineMedicine (R0)